| Identification | Back Directory | [Name]
5-[5,6,7,8-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTHALENYL-METHYL]-N-(2,4,6-TRIMETHOXYPHENYL)-2-FURANCARBOXAMIDE | [CAS]
263847-55-8 | [Synonyms]
AG 045572
5-[5,6,7,8-TETRAHYDRO-3,5,5,8,8-PENTAMETHYL-2-NAPHTHALENYL-METHYL]-N-(2,4,6-TRIMETHOXYPHENYL)-2-FURANCARBOXAMIDE
2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-(2,4,6-trimethoxyphenyl)- | [Molecular Formula]
C30H37NO5 | [MDL Number]
MFCD08272457 | [MOL File]
263847-55-8.mol | [Molecular Weight]
491.62 |
| Hazard Information | Back Directory | [Uses]
AG 045572 is a nonpeptidic GnRH antagonist and has the potential as an oral therapeutic treatement for sex hormone-dependent diseases and infertility. | [Biological Activity]
Selective gonadotropin-releasing hormone (GnRH) receptor antagonist (K i values are 2.2, 3.8 and 6.0 nM for mouse, rat and human receptors respectively). Suppresses testosterone and luteinising hormone (LH) levels in vivo . | [in vivo]
AG-045572 (10 mg/kg (i.v.) or 20 mg/kg (p.o.), one time) give to intact male rats, it showed medium T1/2, CL and Vss but oral bioavailability was low, in female rats the bioavailability was much higher (24%), in castrated male rats the pharmacokinetics was similar to that in female rats[1].
AG-045572 (40 mg/kg, i.m. twice a day for 3 days) pretreated of intact male rats resulted in a change of its pharmacokinetics, the parameters became similar to those in female and castrated male rats[1].
Pharmacokinetic Parameters of AG-045572 in Rats after Administration at 10 mg/kg i.v. and 20 mg/kg p.o.[1]
Pharmacokinetic Analysis[1]
| Animals | t1/2 (h) | CL (L/h/kg) | Vss (L/kg) | Cmax (μM) | Tmax (h) | Fp.o. (%) | | Male | 1.4 ± 0.1 | 2.2 ± 0.5 | 2.1 ± 0.1 | 0.61 ± 0.21 | 1 | 8 | | Female | 1.7 ± 0.1 | 1.5 ± 0.1 | 2.7 ± 0.4 | 2.31 ± 0.57 | 1 | 24 | | Castrated male | 1.7 ± 0.4 | 1.5 ± 0.3 | 3.7 ± 1.5 | 1.98 ± 0.51 | 1 | 23 | | Pretreated male | 1.9 ± 0.2 | 1.5 ± 0.2 | 2.0 ± 0.6 | 1.89 ± 0.41 | 1 | 27 |
| Animal Model: | Male rats were surgically castrated via scrotal approach under halothane anesthesia and allowed 14 days post-operative recovery prior to study[1] | | Dosage: | 10 mg/kg, 20 mg/kg; 40 mg/kg | | Administration: | administered acutely at 10 mg/kg (i.v.) or 20 mg/kg (p.o.), one time; For multiple-dose pretreatment, male rats at 40 mg/kg, i.m. twice a day for 3 days. | | Result: | Showed medium T1/2, CL and Vss but oral bioavailability was low, in female rats the bioavailability was much higher (24%)
Became similar to those in female and castrated male rats.
|
| [storage]
Store at RT | [References]
[1]. barnes mj, burschka c, büttner mw, et al. silicon analogues of the nonpeptidic gnrh antagonist ag-045572: syntheses, crystal structure analyses, and pharmacological characterization. chemmedchem, 2011, 6(11): 2070-2080.
[2]. zhu yf, chen c, struthers rs. nonpeptide gonadotropin releasing hormone antagonists. annu. rep. med. chem, 2004, 39(99): 110.
[3]. anderes kl, luthin dr, castillo r, et al. biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (gnrh) antagonist using castrated and intact rats. journal of pharmacology and experimental therapeutics, 2003, 305(2): 688-695.
[4]. herbst kl. gonadotropin-releasing hormone antagonists. current opinion in pharmacology, 2003, 3(6): 660-666. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 19945035818 |
| Website: |
http://www.topule.com/ |
|